Company: OPGN
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001829126-25-009312
Chunk: 39

Company: OPGEN INC
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
 31, 2025, up to $7.0 million of additional shares of common stock. 

In the near term, we anticipate funding our operations primarily through financing arrangements
with AEI Capital Ltd., including the August 2024 Securities Purchase Agreement noted above, until our operating business is able to sustain
our operations.

27

Sources and uses of cash

The following table summarizes the net cash and cash equivalents (used in) provided by operating activities, investing activities and financing activities for the periods indicated:

    Nine months ended September 30,

    2025

    2024

    Net cash (used in) provided by

     Operating activities
     
    $
    (978,685
    )
     
    $
    (4,637,508
    )
  
     Investing activities

    -

    -

    Financing activities

    82,243

    5,118,851

    Net (decrease) increase in cash and cash equivalents
     
    $
    (896,442
    )
     
    $
    481,343

Net cash used in operating activities

Net cash used in operating activities for the nine months ended September 30, 2025 consists
primarily of our net income of $2.5 million and non-cash share-based compensation expense of $0.3 million, reduced by changes in
operating assets and liabilities of $3.9 million.

Net cash used in operating activities for the nine months ended September 30, 2024 consisted
primarily of our net income of $7.6 million and non-cash share-based compensation expense of $0.6 million, reduced by certain non-cash
items, including the change in the fair value of the EIB loan guaranty of $10.9 million, gain on impairment adjustment of $2.1 million,
and gain on settlement of compensation expenses of $0.6 million.

Net cash used in investing activities

We used no cash in investing activities during the nine months ended September 30, 2025 or 2024.

Net cash provided by financing activities

Net cash provided by financing activities for the nine months ended September 30, 2025 consists solely of proceeds and payments related to our short-term insurance financing.

Net cash provided by financing activities for the nine months ended September 30, 2024 consisted primarily of proceeds from the issuance of preferred stock in connection with the March 2024 Purchase Agreement with David E.